Cargando…

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Anti-PD-1 therapy yields objective clinical responses in 30–40% of advanced melanoma patients. Since most patients do not respond, predictive biomarkers to guide treatment selection are needed. We hypothesize that MHC-I/II expression is required for tumour antigen presentation and may predict anti-P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Douglas B., Estrada, Monica V., Salgado, Roberto, Sanchez, Violeta, Doxie, Deon B., Opalenik, Susan R., Vilgelm, Anna E., Feld, Emily, Johnson, Adam S., Greenplate, Allison R., Sanders, Melinda E., Lovly, Christine M., Frederick, Dennie T., Kelley, Mark C., Richmond, Ann, Irish, Jonathan M., Shyr, Yu, Sullivan, Ryan J., Puzanov, Igor, Sosman, Jeffrey A., Balko, Justin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740184/ https://www.ncbi.nlm.nih.gov/pubmed/26822383 http://dx.doi.org/10.1038/ncomms10582

Ejemplares similares

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
por: Luo, Na, et al.
Publicado: (2018)

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
por: James, Jamaal L, et al.
Publicado: (2023)

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
por: Kanz, Bridgette A., et al.
Publicado: (2016)

Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
por: Morales-Betanzos, Carlos A., et al.
Publicado: (2017)

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
por: Luo, Na, et al.
Publicado: (2018)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017)

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
por: Taylor, Brandie C., et al.
Publicado: (2022)

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
por: Tu, Jingyao, et al.
Publicado: (2022)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2017)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
por: Gonzalez-Ericsson, Paula I., et al.
Publicado: (2021)

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
por: Page, David B., et al.
Publicado: (2019)

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
por: Vilgelm, Anna E., et al.
Publicado: (2019)

Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer
por: Hanna, Ann, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia
por: Gilbert, Julie R, et al.
Publicado: (2022)

Multi-center, pragmatic, cluster-randomized, controlled trial of standardized peritoneal dialysis (PD) training versus usual care on PD-related infections (the TEACH-PD trial): trial protocol
por: Chow, Josephine S. F., et al.
Publicado: (2023)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment
por: Grenga, Italia, et al.
Publicado: (2014)

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
por: Yi, Ruibin, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling
por: Carter, Rachel, et al.
Publicado: (2023)

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

The reactions $pd \to ^{3}He\eta$ and $pd \to ^{3}He\pi^{+}\pi^{-}$ near the $\eta$ threshold
por: Mayer, B, et al.
Publicado: (1995)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors
por: Fu, Yujie, et al.
Publicado: (2020)

HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior
por: Senosain, Maria-Fernanda, et al.
Publicado: (2021)

$\rho$-decays in pd annihilation
por: Pick, B
Publicado: (2000)

A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

High spin states in $^{107}$Pd, $^{108}$Pd, and $^{109}$Ag
por: Pohl, K R, et al.
Publicado: (1996)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_41ujf2m8aibch3fc3035e4hjh9